fbpx

Nyheder

Lundbeckfonden Emerge nyheder

– Data to be Presented at the ESMO Virtual Congress 2020 – Melanoma trial (MM1636) shows best-in-class efficacy data in first line melanoma of IO102 and IO103 in combination with nivolumab (anti-PD1 antibody) Copenhagen, Denmark – September 18, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology,...
Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for neuromuscular disorders, today announces that it has received approval from the Dutch ethics committee and regulatory authorities to advance its development candidate, NMD670, into clinical trials as a novel treatment for the symptoms of myasthenia...
SAN DIEGO and COPENHAGEN, April 22, 2020 /PRNewswire/ — AFYX Therapeutics (“AFYX”), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that its Rivelin® Clobetasol patch (“Rivelin-CLO”) met the primary and multiple secondary endpoints in a Phase 2b study in patients with oral lichen planus (“OLP”). In the largest randomized, double-blind, placebo-controlled...
Data position the company to start potential registrational trials with two drugs in two tumor types Copenhagen, Denmark – February 25, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing Phase 2 trial (IO102-012/KEYNOTE-764) of...
SAN DIEGO and COPENHAGEN, Denmark, Oct. 9, 2019 /PRNewswire/ — AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced results from a Phase 1 clinical proof of concept study evaluating the use of the Rivelin® bio-adhesive patch in patients with vulvar lichen sclerosus (VLS), a painful genital skin condition that affects up to 3% of post-menopausal women....
I april rejser 23 danske biotek-startups til konference i New York, hvor de over to dage får muligheden for at præsentere sig for en række amerikanske investorer. 10. og 11. april får amerikanske investorer og danske biotekvirksomheder mulighed for at møde hinanden til konferencen DKBIO i New York. Blandt de danske virksomheder er SNIPR Biome,...
SNIPR BIOME henter 50 mio. dollars i finansiering fra en gruppe investorer ledet af Lundbeckfonden. Det er bl.a. lykkedes at få en professionel dansk investor, der ikke er kendt for at investere i dansk biotek, med. Potentialet i det CRISPR/cas-baserede danske biotekselskab SNIPR BIOME er så stort, at en gruppe investorer med Lundbeckfonden i spidsen...
Andreas Jurgeit
Andreas Jurgeit er – med tiltrædelse den 1. januar 2019 – blevet ansat som ny partner i Lundbeckfonden Emerge, fondens investeringsenhed med fokus på tidlige biotekinvesteringer. Igennem de sidste ti år har Andreas spillet en aktiv rolle i biotekbranchen. Han stiftede første gang bekendtskab med biotek under sit ph.d.-studium, da han som forsker samarbejdede med...
Copenhagen, Denmark – September 27th, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, announces that the first patient has received the first dose in an international Phase I/II clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA® (pembrolizumab) for patients with non-small...
1 2

Lundbeckfonden Emerge

Nyheder

IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent
18. september 2020
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
14. juli 2020
AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus
22. april 2020